Drug Trial Radar · NCT02646748
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
159
Actual
Start
Jan 25, 2016
Primary completion
Nov 7, 2019
Study completion Nov 20, 2020
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jan 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2). Two treatment groups (Group A and Group B) will be evaluated Part 1a utilizes a 3+3 design to evaluate pembrolizumab and INCB combinations in advanced solid tumors. Group A will evaluate a JAK inhibitor with JAK1 selectivity itacitinib (INCB039110) in combination with pembrolizumab (MK-3475) and Group B will evaluate a PI3K-delta inhibitor (INCB050465) in combination with pembrolizumab to determine the maximum tolerated dose (MTD) or PAD and recommend a dose for the Part 1b safety expansion with each combination. Once the recommended dose has been identified in Part 1a, subjects with select solid tumor types will be enrolled into safety expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b) for each combination. Part 2 utilizes a Simon 2-Stage design to evaluate INCB050465 in combination with pembrolizumab in patients with small cell lung cancer (SCLC) and a 1 stage design to evaluate the combination in patients with non-small cell lung cancer (NSCLC) and urothelial cancer (UC).
Conditions
- Colorectal Cancer (CRC)
- Endometrial Cancer
- Melanoma
- Head and Neck Cancer
- Lung Cancer
- MMR-deficient Tumors
- Breast Cancer
- Pancreatic Cancer
- Renal Cell Carcinoma (RCC)
- Solid Tumors
- UC (Urothelial Cancer)
Interventions
PembrolizumabDrug
Pembrolizumab 200 mg IV Q3W.
itacitinibDrug
Itacitinib tablets administered orally once daily.
INCB050465Drug
INCB050465 tablets administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Evaluation of safety and tolerability as measured by the frequency, duration, and severity of adverse eventsTime frame: Duration of study treatment and up to 120 days after the last dose of study drug
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California
John Wayne Cancer Institute at Providence Saint John's Health Center
Santa Monica, California
Georgetown University Medical Center Lombardi CCC
Washington D.C., District of Columbia
Hematology-Oncology Associates of Treasure Coast
Port Saint Lucie, Florida
Emory University, Winship Cancer Institute
Atlanta, Georgia
University of Kentucky, Markey Cancer Center
Lexington, Kentucky
The Center for Cancer and Blood Disorders (RCCA MD LLC-Maryland Vidision)
Bethesda, Maryland
Beth Israel Medical Deaconess Medical Center
Boston, Massachusetts
Dana Farber Cancer institute
Boston, Massachusetts
Karmanos Cancer Center
Detroit, Michigan
Henry Ford Hospital System
Detroit, Michigan
St. Luke's Hospital of Kansas City
Kansas City, Missouri
NYU Laura & Isaac Perlmutter Cancer Center at NYU Langone
New York, New York
Duke Cancer Institute
Durham, North Carolina
UPMC CancerCenters, Hilman Cancer Center
Pittsburgh, Pennsylvania
HOPE Cancer Center of East Texas
Tyler, Texas
Utah Cancer Specialists
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.